FDA Puts Partial Clinical Hold on BioNTech's ADC Trial After Fatalities

Yahoo FinanceJun 18 11:53 ET

CCORF Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $171

CCORF analyst John Newman maintains $BioNTech(BNTX.US)$ with a buy rating, and maintains the target price at $171.According to TipRanks data, the analyst has a success rate of 39.0% and a total averag

moomoo NewsJun 18 07:31 ET · Ratings

BofA Securities Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $146

BofA Securities analyst Tazeen Ahmad maintains $BioNTech(BNTX.US)$ with a buy rating, and maintains the target price at $146.According to TipRanks data, the analyst has a success rate of 48.3% and a t

moomoo NewsJun 18 05:33 ET · Ratings

US FDA Places Partial Clinical Hold on BioNTech's Cancer Drug Trial

BioNTech's (22UA.F) partner MediLink Therapeutics (Suzhou) notified the company that the US Food and Drug Administration placed a partial hold on new patient enrollment for a phase 1 trial assessing i

MT NewswiresJun 18 00:49 ET

Top Gap Ups and Downs on Monday: AVGO, DELL, SONY and More

Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.

moomoo NewsJun 17 19:40 ET

Express News | BioNTech Shares Are Trading Lower After the FDA Placed a Clinical Hold on Partner Medilink Therapeutics' Phase 1 Trial of BNT326/YL202

BenzingaJun 17 15:09 ET